作者: Joanne M. Ramsey , Alice McCloskey , Rachel Gaul , Elena Fernandez Fernandez , Louise Sweeney
DOI: 10.1007/978-3-030-35910-2_6
关键词:
摘要: Respiratory diseases account for a very significant portion of worldwide morbidity and mortality but to-date only limited number therapeutics are available direct delivery via inhalation. Nanotechnology offers range potential benefits to facilitate the targeted delivery/co-delivery existing therapeutic agents support more advanced biotherapeutics e.g. proteins, gene medicines. The clinical commercial translation inhalable nanomedicines is not trivial presents formulation, manufacturing, assessment regulatory challenges. Herein, we explore respiratory being using nanoparticle-based systems vaccines, composition manufacture these nanoparticles, their integration into relevant inhaler devices, methods used characterize nanoparticles in vitro vivo requirements governing inhaled nanomedicines.